These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 24175258)

  • 1. Treatment of dyslipidemia in chronic kidney disease: Effectiveness and safety of statins.
    Scarpioni R; Ricardi M; Albertazzi V; Melfa L
    World J Nephrol; 2012 Dec; 1(6):184-94. PubMed ID: 24175258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statins for treatment of dyslipidemia in chronic kidney disease.
    Shurraw S; Tonelli M
    Perit Dial Int; 2006; 26(5):523-39. PubMed ID: 16973506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
    Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
    Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].
    Karie S; Launay-Vacher V; Deray G; Isnard-Bagnis C
    Presse Med; 2006 Feb; 35(2 Pt 1):219-29. PubMed ID: 16493350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statin treatment for dyslipidemia in chronic kidney disease and renal transplantation: a review of the evidence.
    Kanbay M; Turgut F; Covic A; Goldsmith D
    J Nephrol; 2009; 22(5):598-609. PubMed ID: 19809992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statins and lipid-lowering strategies in cardiorenal patients.
    Bianchi S; Grimaldi D; Bigazzi R
    Contrib Nephrol; 2011; 171():143-150. PubMed ID: 21625103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia.
    Shrestha P; van de Sluis B; Dullaart RPF; van den Born J
    Cell Signal; 2019 Mar; 55():53-64. PubMed ID: 30550765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dyslipidemia in chronic kidney disease: are statins still indicated in reduction cardiovascular risk in patients on dialysis treatment?
    Scarpioni R; Ricardi M; Melfa L; Cristinelli L
    Cardiovasc Ther; 2010 Dec; 28(6):361-8. PubMed ID: 20553296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease.
    Sharp Collaborative Group
    Am Heart J; 2010 Nov; 160(5):785-794.e10. PubMed ID: 21095263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controversies Regarding Lipid Management and Statin Use for Cardiovascular Risk Reduction in Patients With CKD.
    Markossian T; Burge N; Ling B; Schneider J; Pacold I; Bansal V; Leehey D; Stroupe K; Chang A; Kramer H
    Am J Kidney Dis; 2016 Jun; 67(6):965-77. PubMed ID: 26943983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LDL-cholesterol lowering and renal outcomes.
    Waters DD
    Curr Opin Lipidol; 2015 Jun; 26(3):195-9. PubMed ID: 25887677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statins in chronic kidney disease and kidney transplantation.
    Kassimatis TI; Goldsmith DJ
    Pharmacol Res; 2014 Oct; 88():62-73. PubMed ID: 24995940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statins and kidney disease: is the study of heart and renal protection at the cutting edge of evidence?
    Jenkins M; Goldsmith D
    Curr Opin Cardiol; 2012 Jul; 27(4):429-40. PubMed ID: 22678410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ezetimibe as a potential treatment for dyslipidemia associated with chronic renal failure and renal transplant.
    Ahmed MH; Khalil AA
    Saudi J Kidney Dis Transpl; 2010 Nov; 21(6):1021-9. PubMed ID: 21060168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ezetimibe as a treatment for dyslipidaemia in CKD].
    Żebrowski P; Kaszyńska M
    Wiad Lek; 2019; 72(11 cz 2):2210-2213. PubMed ID: 31860838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.